[go: up one dir, main page]

NO20002470L - Ny materialsammensetning - Google Patents

Ny materialsammensetning

Info

Publication number
NO20002470L
NO20002470L NO20002470A NO20002470A NO20002470L NO 20002470 L NO20002470 L NO 20002470L NO 20002470 A NO20002470 A NO 20002470A NO 20002470 A NO20002470 A NO 20002470A NO 20002470 L NO20002470 L NO 20002470L
Authority
NO
Norway
Prior art keywords
material composition
new material
new
composition
Prior art date
Application number
NO20002470A
Other languages
English (en)
Other versions
NO20002470D0 (no
NO327391B1 (no
Inventor
Ann-Kristin Karlsson
Cheryl Larrivee-Elkins
Ove Molin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20002470(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20002470D0 publication Critical patent/NO20002470D0/no
Publication of NO20002470L publication Critical patent/NO20002470L/no
Publication of NO327391B1 publication Critical patent/NO327391B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/04—Heat
    • A61L2103/05—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
NO20002470A 1997-11-14 2000-05-12 Fremgangsmate for sterilisering av et glukokortikosteroid. NO327391B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704186A SE9704186D0 (sv) 1997-11-14 1997-11-14 New composition of matter
PCT/SE1998/002039 WO1999025359A1 (en) 1997-11-14 1998-11-11 New composition of matter

Publications (3)

Publication Number Publication Date
NO20002470D0 NO20002470D0 (no) 2000-05-12
NO20002470L true NO20002470L (no) 2000-07-05
NO327391B1 NO327391B1 (no) 2009-06-22

Family

ID=20408992

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002470A NO327391B1 (no) 1997-11-14 2000-05-12 Fremgangsmate for sterilisering av et glukokortikosteroid.

Country Status (23)

Country Link
US (3) US6392036B1 (no)
EP (1) EP1032396B1 (no)
JP (2) JP4598268B2 (no)
KR (1) KR100571075B1 (no)
CN (1) CN1173702C (no)
AR (1) AR013765A1 (no)
AT (1) ATE259642T1 (no)
AU (1) AU744992B2 (no)
BR (1) BR9814118A (no)
CA (1) CA2310222C (no)
DE (1) DE69821796T2 (no)
DK (1) DK1032396T3 (no)
ES (1) ES2214749T3 (no)
IL (1) IL136086A (no)
MY (1) MY118856A (no)
NO (1) NO327391B1 (no)
NZ (1) NZ504273A (no)
PT (1) PT1032396E (no)
SA (1) SA99190966B1 (no)
SE (1) SE9704186D0 (no)
TW (1) TWI242436B (no)
WO (1) WO1999025359A1 (no)
ZA (1) ZA9810217B (no)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0810853B1 (en) * 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
AR026073A1 (es) * 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AR026072A1 (es) * 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa
US6787532B2 (en) * 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
WO2002012265A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
NZ526118A (en) * 2000-11-24 2004-10-29 Breath Ltd Sterilisation of pharmaceutical containing glucocorticosteroid by rapid heating and cooling
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US7291608B2 (en) 2001-04-30 2007-11-06 Glaxo Group Limited Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α
GB0130055D0 (en) * 2001-12-14 2002-02-06 Technology Innovation Ltd Medicament packaging
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
AU2003246829A1 (en) * 2002-02-19 2003-09-09 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
KR101020687B1 (ko) 2002-07-02 2011-03-11 니코메드 게엠베하 사이클레소나이드 함유 멸균 수성 현탁액
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
AU2003268380A1 (en) * 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
EP1572217B1 (en) 2002-12-12 2008-08-20 Nycomed GmbH Combination medicament of r,r-formoterol and ciclesonide
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1454636A1 (en) * 2003-03-04 2004-09-08 Dompé S.P.A. Sterilization of glucocorticoid drug particles for pulmonary delivery
ATE477193T1 (de) * 2003-03-15 2010-08-15 Brin Tech Internat Ltd Verpackung für arzneimittel
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2523035C (en) * 2003-05-22 2011-04-26 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0319500D0 (en) 2003-08-19 2003-09-17 Resolution Chemicals Ltd Particle-size reduction apparatus,and use thereof
US8371292B2 (en) 2003-09-16 2013-02-12 Nycomed Gmbh Use of ciclesonide for the treatment of respiratory diseases
PE20050941A1 (es) * 2003-12-16 2005-11-08 Nycomed Gmbh Suspensiones acuosas de ciclesonida para nebulizacion
ATE446581T1 (de) * 2004-03-12 2009-11-15 Trinity College Dublin Magnetoresistives medium
US7892483B2 (en) * 2004-03-12 2011-02-22 Cipla Limited Sterilization process
CA2563556C (en) * 2004-04-20 2013-01-29 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases in a smoking patient
ITMI20040795A1 (it) * 2004-04-23 2004-07-23 Eratech S R L Composizione farmaceutica solida secca suo processo di preparazione e sospensione acquosa stabile ottenuta dalla stessa
GB0410995D0 (en) * 2004-05-17 2004-06-23 Norton Healthcare Ltd Heat sterilization of glucocorticosteroids
ITSA20040012A1 (it) * 2004-09-07 2004-12-07 Genetec S P A Processo di sterilizzazione di un glucocorticosteroide.
GB0425266D0 (en) * 2004-11-16 2004-12-15 Norton Healthcare Ltd Pharmaceutical manufacturing process
GB0427568D0 (en) 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
EP1782839A1 (en) 2005-11-03 2007-05-09 Genetic S.p.A. Sterilization process of Glucocorticosteroid by supercritical CO2
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US20090252801A1 (en) 2005-11-29 2009-10-08 Farmbios S.P.A. Process for the Preparation of Micronised Sterile Steroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070166184A1 (en) * 2006-01-13 2007-07-19 Zimmer Technology, Inc. Methods for cleaning and sterilizing devices
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
CA2642579A1 (en) * 2006-02-15 2007-08-23 Tika Lakemedel Ab Sterilization of corticosteroids with reduced mass loss
FR2898273B1 (fr) * 2006-03-07 2013-11-08 Merck Generiques Procede de sterilisation par chauffage par voie seche d'une poudre comprenant un glucocorticosteroide
EP2043698A2 (en) * 2006-07-20 2009-04-08 Sicor, Inc. Process for the preparation of solid sterile active pharmaceutical ingredient
CN101265342B (zh) * 2007-03-12 2014-04-02 广东炜林纳功能材料有限公司 一种聚丙烯的复合β晶型成核剂
CN102226026B (zh) * 2007-03-12 2013-12-18 广东炜林纳功能材料有限公司 一种聚丙烯的复合β晶型成核剂
CA2705159A1 (en) * 2007-11-09 2009-05-14 Map Pharmaceuticals, Inc. Methods for administering corticosteroid formulations
US8865692B2 (en) 2007-11-13 2014-10-21 Meritage Pharma, Inc Compositions for the treatment of gastrointestinal inflammation
PL3354276T3 (pl) * 2007-11-13 2020-09-21 Meritage Pharma, Inc. Kompozycje do leczenia zapalenia przewodu pokarmowego
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
BRPI0910850B1 (pt) 2008-04-21 2022-06-14 Otonomy, Inc. Composição intratimpânica compreendendo fator neurotrófico de crescimento derivado do cérebro (bdnf) para o tratamento ou prevenção da perda auditiva
CN102026623B (zh) 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US8846770B2 (en) * 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
JP5491502B2 (ja) * 2008-07-14 2014-05-14 オトノミ―，インク． 制御放出アポトーシス調節化合物および耳の障害の処置のための方法
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8399018B2 (en) * 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
CN102105133B (zh) * 2008-07-21 2015-06-17 奥德纳米有限公司 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US9173864B2 (en) 2008-10-22 2015-11-03 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
KR20100079830A (ko) * 2008-12-31 2010-07-08 삼성정밀화학 주식회사 입도 분포가 좁은 토너의 제조방법
EP4420730A3 (en) 2009-03-19 2024-11-13 The Johns Hopkins University Psma-targeting compounds and uses thereof
US20180009767A9 (en) 2009-03-19 2018-01-11 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
US8273725B2 (en) 2009-09-10 2012-09-25 Genzyme Corporation Stable hyaluronan/steroid formulation
WO2011135585A2 (en) * 2010-04-28 2011-11-03 Cadila Healthcare Limited Aqueous pharmaceutical solution of ciclesonide
WO2012150131A1 (en) 2011-05-03 2012-11-08 Chiesi Farmaceutici S.P.A. Improved suspension formulation of a corticosteroid for administration by inhalation
WO2014144309A1 (en) * 2013-03-15 2014-09-18 Oakwood Laboratories Sustained release microspheres and method of producing the same
JP2016534121A (ja) 2013-08-27 2016-11-04 オトノミ—，インク． 小児の耳の病気の処置
NO3193835T3 (no) 2014-09-15 2018-08-04
US10405753B2 (en) 2015-11-10 2019-09-10 Intuitive Surgical Operations, Inc. Pharmaceutical compositions of near IR closed chain, sulfo-cyanine dyes
US11040004B2 (en) 2016-09-16 2021-06-22 Otonomy, Inc. Otic gel formulations for treating otitis externa
WO2018232280A1 (en) 2017-06-15 2018-12-20 The Johns Hopkins University Psma targeted fluorescent agents for image guided surgery
US11344562B2 (en) 2017-08-15 2022-05-31 Nephron Pharmaceuticals Corporation Aqueous nebulization composition
CN107510687B (zh) * 2017-08-18 2020-07-03 南京海纳医药科技股份有限公司 一种供雾化用含有福莫特罗和布地奈德的吸入混悬液及其制备方法
CN108175763B (zh) * 2017-12-19 2020-09-11 亿腾医药（苏州）有限公司 一种布地奈德无菌原料及其吸入用混悬液的制备方法
GB202202297D0 (en) * 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
AU2024309346A1 (en) 2023-06-26 2026-01-08 Verona Pharma Plc Particulate composition comprising ensifetrine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US396430A (en) * 1889-01-22 Helm reichel
US3337400A (en) * 1965-10-08 1967-08-22 Joel P Smith Aqueous post-surgical injection by infiltration with a local anesthetic, a substantially water-insoluble, local anti-inflammatory gluco corticoid, and an antibiotic
US3692430A (en) * 1971-06-18 1972-09-19 John W Timmons Liquid pumping system
US3992534A (en) * 1972-05-19 1976-11-16 Ab Bofors Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
DE2837115A1 (de) * 1978-08-25 1980-03-06 Bayer Ag Neues verfahren zur herstellung von sterilen feststoffen
PT69652A (fr) 1979-05-22 1979-06-01 Quatrum Empresa Nacional De Qu Procede pour la sterilization de produits non stables a hautes temperatures nommement steroides sous la forme de poudre contenus dans une emballage fermee
JPS5732212A (en) 1980-08-07 1982-02-20 Mitsui Toatsu Chem Inc Sterilizing method of acetylsalicylate salt
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
JPH0660106B2 (ja) 1985-11-14 1994-08-10 徳男 斎藤 生薬類を主剤とする滅菌丸剤の製造法
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5380645A (en) * 1989-03-16 1995-01-10 The Johns Hopkins University Generalized method for assessment of colorectal carcinoma
SE8903219D0 (sv) * 1989-10-02 1989-10-02 Astra Ab Process for the manufacture of budesonide
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5491062A (en) * 1993-11-23 1996-02-13 Stratagene Polynucleotide amplification mycoplasma assay, primers, and kits therefore
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US5843644A (en) * 1994-03-01 1998-12-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Isolation of cellular material under microscopic visualization using an adhesive/extraction reagent tipped probe
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US5580728A (en) * 1994-06-17 1996-12-03 Perlin; Mark W. Method and system for genotyping
CA2198774A1 (en) * 1994-09-23 1996-03-28 Sydney D. Finkelstein Topographic genotyping
WO1996009814A1 (en) 1994-09-29 1996-04-04 Andaris Limited Spray-dried microparticles as therapeutic vehicles
US5521168A (en) * 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5700794A (en) * 1994-10-13 1997-12-23 Alcon Laboratories Inc. Treatment of ocular hypotony
US6255483B1 (en) * 1995-03-15 2001-07-03 Ciba Specialty Chemicals Corporation Biphenyl-substituted triazines
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
AU6290396A (en) * 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
JPH0930988A (ja) * 1995-07-21 1997-02-04 Sumitomo Osaka Cement Co Ltd 薬剤徐放性多孔質セラミックス成形体及びその製造方法
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5792758A (en) * 1995-12-08 1998-08-11 G. D. Searle & Co. Steroid nitrite ester derivatives useful as anti-inflammatory drugs
SE9604486D0 (sv) * 1996-12-05 1996-12-05 Astra Ab Novel formulation
DE29717252U1 (de) * 1997-09-26 1998-02-19 Dr. Falk Pharma GmbH, 79108 Freiburg Arzneimittelkit aus einem Budesonid-haltigen und einem Ursodesoxycholsäure-haltigen Arzneimittel zur Behandlung von cholestatischen Lebererkrankungen
ATE216244T1 (de) 1997-10-09 2002-05-15 Schering Corp Mometasonfuroat-suspensionen zum zerstäuben
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
NZ526118A (en) * 2000-11-24 2004-10-29 Breath Ltd Sterilisation of pharmaceutical containing glucocorticosteroid by rapid heating and cooling
AU2003246829A1 (en) 2002-02-19 2003-09-09 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
ITMI20032054A1 (it) * 2003-10-22 2005-04-23 Monteres S R L Processo per la preparazione di sospensioni farmaceutiche da inalare.
US7892483B2 (en) * 2004-03-12 2011-02-22 Cipla Limited Sterilization process

Also Published As

Publication number Publication date
DE69821796D1 (de) 2004-03-25
WO1999025359A1 (en) 1999-05-27
CN1173702C (zh) 2004-11-03
ATE259642T1 (de) 2004-03-15
HK1030549A1 (en) 2001-05-11
AR013765A1 (es) 2001-01-10
US20070197489A1 (en) 2007-08-23
MY118856A (en) 2005-01-31
NO20002470D0 (no) 2000-05-12
ES2214749T3 (es) 2004-09-16
CA2310222A1 (en) 1999-05-27
SA99190966B1 (ar) 2006-03-07
AU1266699A (en) 1999-06-07
US7524834B2 (en) 2009-04-28
JP4598268B2 (ja) 2010-12-15
IL136086A0 (en) 2001-05-20
EP1032396A1 (en) 2000-09-06
PT1032396E (pt) 2004-06-30
US20020065256A1 (en) 2002-05-30
SE9704186D0 (sv) 1997-11-14
IL136086A (en) 2005-05-17
KR20010032088A (ko) 2001-04-16
NO327391B1 (no) 2009-06-22
BR9814118A (pt) 2000-10-03
TWI242436B (en) 2005-11-01
EP1032396B1 (en) 2004-02-18
AU744992B2 (en) 2002-03-07
NZ504273A (en) 2002-10-25
DK1032396T3 (da) 2004-05-24
CA2310222C (en) 2008-05-13
US6392036B1 (en) 2002-05-21
JP2010070567A (ja) 2010-04-02
JP2001523638A (ja) 2001-11-27
ZA9810217B (en) 1999-05-14
KR100571075B1 (ko) 2006-04-14
DE69821796T2 (de) 2005-01-13
CN1285750A (zh) 2001-02-28

Similar Documents

Publication Publication Date Title
NO20002470L (no) Ny materialsammensetning
IS5430A (is) Ný samsetning
DE69802670D1 (de) Flash-gesponnenes flächiges material
ID20005A (id) Komposisi pestisida
ID25508A (id) Komposisi dematologis
DE69827987D1 (de) Verpackungsmaterial
DE69803968D1 (de) Kautschukzusammensetzung
DE69826138D1 (de) Parfümzusammensetzung
ID28852A (id) Bahan-bahan elektroluminesensi
DE69922710D1 (de) Gasadsorbierendes material
ID21009A (id) Komposisi untuk supositori
FI971338A7 (fi) Muovipohjainen materiaali
FI972210A0 (fi) Icke-svettdrivande material
ID23250A (id) Komposisi paroksetin
ID21906A (id) Komposisi adesif
FI974634A0 (fi) Anordning foer matning av material
DE69802332D1 (de) Aufzeichnungsmaterial
PT867124E (pt) Composicao antifungica
ID21454A (id) Komposisi pestisida
DE69804218D1 (de) Zementzusammensetzung
DE69803996D1 (de) Verpackungsmaterial
NO20005483L (no) Ny sammensetning
ID24191A (id) Komposisi baru
DE69832430D1 (de) PTC-Verbundmaterial
DE69828708D1 (de) Deodorant-zusammensetzung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees